Canaccord Genuity Initiates Coverage On Amgen with Hold Rating, Announces Price Target of $366

Benzinga Newsdesk www.benzinga.com Neutral 75.8%

Neg 0% Neu 75.8% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on Amgen (NASDAQ:AMGN) with a Hold rating and announces Price Target of $366.